The Efficacy of Pharmacotherapy for Decreasing the Expansion Rate of Abdominal Aortic Aneurysms: A Systematic Review and Meta-Analysis
Open Access
- 26 March 2008
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 3 (3), e1895
- https://doi.org/10.1371/journal.pone.0001895
Abstract
Pharmacotherapy may represent a potential means to limit the expansion rate of abdominal aortic aneurysms (AAAs). Studies evaluating the efficacy of different pharmacological agents to slow down human AAA-expansion rates have been performed, but they have never been systematically reviewed or summarized. Two independent reviewers identified studies and selected randomized trials and prospective cohort studies comparing the growth rate of AAA in patients with pharmacotherapy vs. no pharmacotherapy. We extracted information on study interventions, baseline characteristics, methodological quality, and AAA growth rate differences (in mm/year). Fourteen prospective studies met eligibility criteria. Five cohort studies raised the possibility of benefit of beta-blockers [pooled growth rate difference: −0.62 mm/year, (95%CI, −1.00 to −0.24)], but this was not confirmed in three beta-blocker RCTs [pooled RCT growth rate difference: −0.05 mm/year (−0.16 to 0.05)]. Statins have been evaluated in two cohort studies that yield a pooled growth rate difference of −2.97 (−5.83 to −0.11). Doxycycline and roxithromycin have been evaluated in two RCTs that suggest possible benefit [pooled RCT growth rate difference: −1.32 mm/year (−2.89 to 0.25)]. Studies assessing NSAIDs, diuretics, calcium channel blockers and ACE inhibitors, meanwhile, did not find statistically significant differences. Beta-blockers do not appear to significantly reduce the growth rate of AAAs. Statins and other anti-inflammatory agents appear to hold promise for decreasing the expansion rate of AAA, but need further evaluation before definitive recommendations can be made.This publication has 56 references indexed in Scilit:
- Pharmacological targets in the treatment of abdominal aortic aneurysmsEmerging Therapeutic Targets, 2006
- Getting It Right: Being Smarter about Clinical TrialsPLoS Medicine, 2006
- Mortality and Size of Abdominal Aortic Aneurysm at Long-Term Follow-Up of Patients Not Treated Surgically and Treated With and Without StatinsThe American Journal of Cardiology, 2006
- Does the Prentice criterion validate surrogate endpoints?Statistics in Medicine, 2004
- Are antihypertensive drugs associated with abdominal aortic aneurysms?Journal of Vascular Surgery, 2002
- Are antihypertensive drugs associated with abdominal aortic aneurysms?Journal of Vascular Surgery, 2002
- Smoking, but not Lipids, Lipoprotein (a) and Antibodies Against Oxidised LDL, is Correlated to the Expansion of Abdominal Aortic AneurysmsEuropean Journal of Vascular and Endovascular Surgery, 2001
- Effect of propanolol on the expansion of abdominal aortic aneurysms: a randomized studyBritish Journal of Surgery, 2000
- Suppression of Experimental Aneurysmal Degeneration with Chemically Modified Tetracycline DerivativesaAnnals of the New York Academy of Sciences, 1996
- Assessing the quality of reports of randomized clinical trials: Is blinding necessary?Controlled Clinical Trials, 1996